VMAT1 deletion causes neuronal loss in the hippocampus and neurocognitive deficits in spatial discrimination

Neuroscience

Volumn 232, Issue , 2013, Pages 32-44

  Multani, P K ^a   Hodge, R ^a   Estevez M A ^b   Abel, T ^a,b   Kung, H ^a   Alter, M ^a   Brookshire, B ^a   Lucki, I ^a   Nall, A H ^a   Talbot, K ^a   Doyle, G A ^a   Lohoff, F W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Cognition; Hippocampus; Neurogenesis; SLC18A1

Indexed keywords

BROXURIDINE; CASPASE 3; VESICULAR MONOAMINE TRANSPORTER 1; VESICULAR MONOAMINE TRANSPORTER 2; CASP3 PROTEIN, MOUSE; MESSENGER RNA; SLC18A1 PROTEIN, MOUSE; SLC18A2 PROTEIN, MOUSE; SYNAPTOPHYSIN; SYP PROTEIN, MOUSE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN NERVE CELL; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROCOGNITIVE DEFICIT; NEUROLOGIC DISEASE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPATIAL DISCRIMINATION; VMAT1 GENE; WILD TYPE; ANIMAL; BRAIN; COGNITIVE DEFECT; CONDITIONING; DEFICIENCY; DEPTH PERCEPTION; FEAR; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PERCEPTIVE DISCRIMINATION; PHYSIOLOGY; RECOGNITION;

ANIMALS; APOPTOSIS; BRAIN; CASPASE 3; COGNITION DISORDERS; CONDITIONING (PSYCHOLOGY); DISCRIMINATION (PSYCHOLOGY); FEAR; MALE; MICE, KNOCKOUT; NEUROGENESIS; NEURONS; RECOGNITION (PSYCHOLOGY); RNA, MESSENGER; SPACE PERCEPTION; SYNAPTOPHYSIN; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84872401712     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.11.023     Document Type: Article

References (56)

1. Ashe K.M., Chiu W.L., Khalifa A.M., Nicolas A.N., Brown B.L., De Martino R.R., Alexander C.P., Waggener C.T., Fischer-Stenger K., Stewart J.K. Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain. Neuro Endocrinol Lett 2011, 32:253-258.
2. Balu D.T., Hodes G.E., Hill T.E., Ho N., Rahman Z., Bender C.N., Ring R.H., Dwyer J.M., Rosenzweig-Lipson S., Hughes Z.A., Schechter L.E., Lucki I. Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse. J Pharmacol Toxicol Methods 2009, 59:100-107.
3. Benes F.M., Kwok E.W., Vincent S.L., Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 1998, 44:88-97.
4. Bly M. Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia. Schizoph Res 2005, 78:337-338.
5. Breunig J.J., Silbereis J., Vaccarino F.M., Sestan N., Rakic P. Notch regulates cell fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus. Proc Natl Acad Sci USA 2007, 104:20558-20563.
6. Brunk I., Blex C., Rachakonda S., Holtje M., Winter S., Pahner I., Walther D.J., Ahnert-Hilger G. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake. J Biol Chem 2006, 281:33373-33385.
7. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., Colebrooke R.E., Di Monte D.A., Emson P.C., Miller G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007, 27:8138-8148.
8. Chen S.F., Chen C.H., Chen J.Y., Wang Y.C., Lai I.C., Liou Y.J., Liao D.L. Support for association of the A277C single nucleotide polymorphism in human vesicular monoamine transporter 1 gene with schizophrenia. Schizophr Res 2007, 90:363-365.
9. Eiden L.E., Schafer M.K., Weihe E., Schutz B. The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 2004, 447:636-640.
10. Eiden L.E., Weihe E. VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse. Ann NY Acad Sci 2011, 1216:86-98.
11. Ellis J.D., German C.L., Birdsall E., Hanson J.E., Crosby M.A., Rowley S.D., Sawada N.A., West J.N., Hanson G.R., Fleckenstein A.E. Ephedrine decreases vesicular monoamine transporter-2 function. Synapse 2011, 65:449-451.
12. Erickson J.D., Schafer M.K., Bonner T.I., Eiden L.E., Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996, 93:5166-5171.
13. Fleckenstein A.E., Volz T.J., Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 2009, 56(Suppl. 1):133-138.
14. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007, 47:681-698.
15. Fon E.A., Pothos E.N., Sun B.C., Killeen N., Sulzer D., Edwards R.H. Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 1997, 19:1271-1283.
16. Frankland P.W., Cestari V., Filipkowski R.K., McDonald R.J., Silva A.J. The dorsal hippocampus is essential for context discrimination but not for contextual conditioning. Behav Neurosci 1998, 112:863-874.
17. Fukui M., Rodriguiz R.M., Zhou J., Jiang S.X., Phillips L.E., Caron M.G., Wetsel W.C. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci 2007, 27:10520-10529.
18. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 1999, 19:2424-2431.
19. Hall F.S., Sora I., Uhl G.R. Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 2003, 28:620-628.
20. Hansson S.R., Hoffman B.J., Mezey E. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2. I. The developing rat central nervous system. Brain Res Dev Brain Res 1998, 110:135-158.
21. Harvey P.D., Wingo A.P., Burdick K.E., Baldessarini R.J. Cognition and disability in bipolar disorder: lessons from schizophrenia research. Bipolar Disord 2010, 12:364-375.
22. Ibanez-Sandoval O., Tecuapetla F., Unal B., Shah F., Koos T., Tepper J.M. Electrophysiological and morphological characteristics and synaptic connectivity of tyrosine hydroxylase-expressing neurons in adult mouse striatum. J Neurosci 2010, 30:6999-7016.
23. Konradi C., Yang C.K., Zimmerman E.I., Lohmann K.M., Gresch P., Pantazopoulos H., Berretta S., Heckers S. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res 2011, 131:165-173.
24. Little K.Y., Krolewski D.M., Zhang L., Cassin B.J. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003, 160:47-55.
25. Liu Y., Peter D., Roghani A., Schuldiner S., Prive G.G., Eisenberg D., Brecha N., Edwards R.H. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. Cell 1992, 70:539-551.
26. Lohoff F.W., Dahl J.P., Ferraro T.N., Arnold S.E., Gallinat J., Sander T., Berrettini W.H. Variations in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) are associated with bipolar i disorder. Neuropsychopharmacology 2006, 31:2739-2747.
27. Lohoff F.W., Lautenschlager M., Mohr J., Ferraro T.N., Sander T., Gallinat J. Association between variation in the vesicular monoamine transporter 1 gene on chromosome 8p and anxiety-related personality traits. Neurosci Lett 2008, 434:41-45.
28. Lohoff F.W., Weller A.E., Bloch P.J., Buono R.J., Doyle G.A., Ferraro T.N., Berrettini W.H. Association between polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology 2008, 57:55-60.
29. Madsen T.M., Kristjansen P.E., Bolwig T.G., Wortwein G. Arrested neuronal proliferation and impaired hippocampal function following fractionated brain irradiation in the adult rat. Neuroscience 2003, 119:635-642.
30. McFadden L., Hadlock G.C., Allen S.C., Vieira-Brock P.L., Stout K.A., Ellis J.D., Hoonakker A.J., Anderyak D.M., Neilson S.M., Wilkins D.G., Hanson G.R., Fleckenstein A.E. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. The. J Pharmacol Exp Ther 2011.
31. McFadden L.M., Stout K.A., Vieira-Brock P.L., Allen S.C., Nielsen S.M., Wilkins D.G., Hanson G.R., Fleckenstein A.E. Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 2011.
32. Narboux-Neme N., Sagne C., Doly S., Diaz S.L., Martin C.B., Angenard G., Martres M.P., Giros B., Hamon M., Lanfumey L., Gaspar P., Mongeau R. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology 2011, 36:2538-2550.
33. Need A.C., Keefe R.S., Ge D., Grossman I., Dickson S., McEvoy J.P., Goldstein D.B. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet 2009, 17:946-957.
34. Oliveira A.M., Hawk J.D., Abel T., Havekes R. Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. Learn Mem 2010, 17:155-160.
35. Peter D., Finn J.P., Klisak I., Liu Y., Kojis T., Heinzmann C., Roghani A., Sparkes R.S., Edwards R.H. Chromosomal localization of the human vesicular amine transporter genes. Genomics 1993, 18:720-723.
36. Peter D., Liu Y., Sternini C., de Giorgio R., Brecha N., Edwards R.H. Differential expression of two vesicular monoamine transporters. J Neurosci 1995, 15:6179-6188.
37. Reif A., Schmitt A., Fritzen S., Lesch K.P. Neurogenesis and schizophrenia: dividing neurons in a divided mind?. Eur Arch Psychiatry Clin Neurosci 2007, 257:290-299.
38. Richards M., Iijima Y., Kondo H., Shizuno T., Hori H., Arima K., Saitoh O., Kunugi H. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct 2006, 2:39.
39. Sahay A., Wilson D.A., Hen R. Pattern separation: a common function for new neurons in hippocampus and olfactory bulb. Neuron 2011, 70:582-588.
40. Savelieva K.V., Caudle W.M., Miller G.W. Altered ethanol-associated behaviors in vesicular monoamine transporter heterozygote knockout mice. Alcohol 2006, 40:87-94.
41. Snyder J.S., Choe J.S., Clifford M.A., Jeurling S.I., Hurley P., Brown A., Kamhi J.F., Cameron H.A. Adult-born hippocampal neurons are more numerous, faster maturing, and more involved in behavior in rats than in mice. J Neurosci 2009, 29:14484-14495.
42. Snyder J.S., Hong N.S., McDonald R.J., Wojtowicz J.M. A role for adult neurogenesis in spatial long-term memory. Neuroscience 2005, 130:843-852.
43. Soetanto A., Wilson R.S., Talbot K., Un A., Schneider J.A., Sobiesk M., Kelly J., Leurgans S., Bennett D.A., Arnold S.E. Association of anxiety and depression with microtubule-associated protein 2- and synaptopodin-immunolabeled dendrite and spine densities in hippocampal CA3 of older humans. Arch Gen Psychiatry 2010, 67:448-457.
44. Stankovski L., Alvarez C., Ouimet T., Vitalis T., El-Hachimi K.H., Price D., Deneris E., Gaspar P., Cases O. Developmental cell death is enhanced in the cerebral cortex of mice lacking the brain vesicular monoamine transporter. J Neurosci 2007, 27:1315-1324.
45. Takahashi N., Miner L.L., Sora I., Ujike H., Revay R.S., Kostic V., Jackson-Lewis V., Przedborski S., Uhl G.R. VMAT2 knockout mice. heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997, 94:9938-9943.
46. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am J Psychiatry 2010, 167:1178-1193.
47. Taylor T.N., Caudle W.M., Miller G.W. VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson's disease. Parkinsons Dis 2011, 2011:124165.
48. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008, 62:873-876.
49. Tronel S., Belnoue L., Grosjean N., Revest J.M., Piazza P.V., Koehl M., Abrous D.N. Adult-born neurons are necessary for extended contextual discrimination. Hippocampus 2012, 22:292-298.
50. Uhl G.R., Li S., Takahashi N., Itokawa K., Lin Z., Hazama M., Sora I. The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB J 2000, 14:2459-2465.
51. Vergo S., Johansen J.L., Leist M., Lotharius J. Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. Brain Res 2007, 1185:18-32.
52. Vieira-Brock P.L., Miller E.I., Nielsen S.M., Fleckenstein A.E., Wilkins D.G. Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2011, 879:3465-3474.
53. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., Caron M.G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997, 19:1285-1296.
54. Yamamoto H., Kamegaya E., Hagino Y., Imai K., Fujikawa A., Tamura K., Enokiya T., Yamamoto T., Takeshima T., Koga H., Uhl G.R., Ikeda K., Sora I. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochem Int 2007, 51:237-244.
55. Zubieta J.K., Huguelet P., Ohl L.E., Koeppe R.A., Kilbourn M.R., Carr J.M., Giordani B.J., Frey K.A. High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry 2000, 157:1619-1628.
56. Zubieta J.K., Taylor S.F., Huguelet P., Koeppe R.A., Kilbourn M.R., Frey K.A. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 2001, 49:110-116.